Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

This fact sheet provides an overview of data on dietary acrylamide and the risk of developing cancer.

Dietary Acrylamide and Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

October 11, 2019

This fact sheet provides an overview of data on dietary acrylamide and the risk of developing cancer.

This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers.

ESMO Clinical Practice Guidelines for Surveillance of Hereditary Gastrointestinal Cancers

By

Andrea S. Blevins Primeau, PhD, MBA

September 20, 2019

This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers.

This fact sheet describes the potential role of dietary flavonoids in reducing cancer risk.

Flavonoids and Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

August 9, 2019

This fact sheet describes the potential role of dietary flavonoids in reducing cancer risk.

This fact sheet explains biosimilars: what they are, how they differ from the original biologic, and their availability.

Biosimilar Therapies for Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

July 26, 2019

This fact sheet explains biosimilars: what they are, how they differ from the original biologic, and their availability.

This fact sheet explains the processes involved in drug development and FDA drug approval.

Cancer Drug Development: How Therapies Move Through the Pipeline

By

Andrea S. Blevins Primeau, PhD, MBA

July 12, 2019

This fact sheet explains the processes involved in drug development and FDA drug approval.

This fact sheet provides the meaning of oncology lingo that patients may commonly hear following a cancer diagnosis.

A Glossary of Cancer Terms for Patients

By

Andrea S. Blevins Primeau, PhD, MBA

June 21, 2019

This fact sheet provides the meaning of oncology lingo that patients may commonly hear following a cancer diagnosis.

This fact sheet describes some of the panels used to detect genomic aberrations and guide treatment decisions.

Next-Generation Sequencing for Patients: What Test Will I Get?

By

Andrea S. Blevins Primeau, PhD, MBA

June 14, 2019

This fact sheet describes some of the panels used to detect genomic aberrations and guide treatment decisions.

At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progre

Adverse Events Associated With Outcomes in PD-1/PD-L1–Treated Urothelial Carcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

June 6, 2019

An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.

Clinic trial research

Synthetic Control Arm Replicates Outcomes From Historical Data

By

Andrea S. Blevins Primeau, PhD, MBA

June 5, 2019

A synthetic control arm based on pooled historical data successfully replicated clinical outcomes.

“BRAF-mutated NSCLC represents an emerging targetable entity among the scenario of oncogene-driven N

Osimertinib Associated With Higher Rates of Cardiotoxicity Than Other EGFR TKIs

By

Andrea S. Blevins Primeau, PhD, MBA

June 5, 2019

A FAERS analysis demonstrated that osimertinib is associated with increased odds of developing cardiotoxicities compared with other EGFR TKIs.

Next post in ASCO 2019

In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly i

Depth of Response to TKIs, Immunotherapies Correlates to Longer PFS and OS